Putative Function of Arthropod Vectors in African Swine Fever Virus Transmission in Relation to Their Bio-Ecological Properties
African swine fever (ASF) is likely one of the most essential ailments in Suidae because of its important well being and socioeconomic penalties and represents a significant menace to the European pig business, particularly within the absence of any accessible remedy or vaccine. In truth, with its excessive mortality price and the next commerce restrictions imposed on affected international locations, ASF can dramatically disrupt the pig business in international locations.
In September 2018, ASF was unexpectedly recognized in wild boars from southern Belgium within the province of Luxembourg, not removed from the Franco-Belgian border. The French authorities quickly commissioned an knowledgeable opinion on the danger of ASF introduction and dissemination into metropolitan France. In Europe, the primary transmission routes of the virus comprise direct contact between contaminated and vulnerable animals and oblique transmission via contaminated materials or feed.
Nevertheless, the seasonality of the illness in some pig farms in Baltic international locations, together with outbreaks in farms with excessive biosecurity ranges, have led to questions on the attainable involvement of arthropods within the transmission of the virus. This evaluate explores the present physique of data on the commonest arthropod households current in metropolitan France. We study their potential function in spreading ASF-by lively organic or mechanical transmission or by passive transport or ingestion-in relation to their bio-ecological properties.
It additionally highlights the existence of serious gaps in our data on vector ecology in home and wild boar environments and in vector competence for ASFV transmission. Filling these gaps is crucial to additional understanding ASF transmission with a purpose to thus implement applicable administration measures.
KIR2DL4 siRNA (Human) |
|||
MBS8221428-30nmol | MyBiosource | 30nmol | EUR 565 |
KIR2DL4 siRNA (Human) |
|||
MBS8221428-5x30nmol | MyBiosource | 5x30nmol | EUR 2450 |
PE anti-human CD158d (KIR2DL4) |
|||
E16FHP158d-025 | EnoGene | 25 tests | EUR 541.67 |
Description: Available in various conjugation types. |
PE anti-human CD158d (KIR2DL4) |
|||
E16FHP158d-100 | EnoGene | 100 tests | EUR 1278.33 |
Description: Available in various conjugation types. |
APC anti-human CD158d (KIR2DL4) |
|||
E16FHA158d-025 | EnoGene | 25 tests | EUR 563.33 |
Description: Available in various conjugation types. |
APC anti-human CD158d (KIR2DL4) |
|||
E16FHA158d-100 | EnoGene | 100 tests | EUR 1321.67 |
Description: Available in various conjugation types. |
Human KIR2DL4 ELISA KIT |
|||
ELI-21303h | Nova Lifetech | 96tests | EUR 696 |
Human KIR2DL4 shRNA Plasmid |
|||
20-abx952576 | Abbexa |
|
|
Mouse Monoclonal anti-human KIR2DL4 |
|||
hAP-0441 | Angio Proteomie | 100ug | EUR 250 |
Human KIR2DL4 Protein Lysate |
|||
MBS8414061-002mg | MyBiosource | 0.02mg | EUR 365 |
Human KIR2DL4 Protein Lysate |
|||
MBS8414061-5x002mg | MyBiosource | 5x0.02mg | EUR 1410 |
Recombinant Human KIR2DL4 Protein |
|||
MBS8249336-001mg | MyBiosource | 0.01mg | EUR 210 |
Recombinant Human KIR2DL4 Protein |
|||
MBS8249336-005mg | MyBiosource | 0.05mg | EUR 420 |
Recombinant Human KIR2DL4 Protein |
|||
MBS8249336-05mg | MyBiosource | 0.5mg | EUR 2420 |
Recombinant Human KIR2DL4 Protein |
|||
MBS8249336-5x05mg | MyBiosource | 5x0.5mg | EUR 10810 |
Human KIR2DL4 Protein, Fc Tag |
|||
E40KMPH4155 | EnoGene | 20ug | EUR 495 |
Human KIR2DL4 Protein, Fc Tag |
|||
E40KMPH4156 | EnoGene | 20ug | EUR 495 |
KIR2DL4 Recombinant Protein (Human) |
|||
RP017041 | ABM | 100 ug | Ask for price |
KIR2DL4 Protein, Human, Recombinant |
|||
MBS8121253-01mg | MyBiosource | 0.1mg | EUR 395 |
KIR2DL4 Protein, Human, Recombinant |
|||
MBS8121253-5x01mg | MyBiosource | 5x0.1mg | EUR 1635 |
NE Purified anti-human CD158d (KIR2DL4) |
|||
E16FHY158d-050U | EnoGene | 50 μg | EUR 845 |
Description: Available in various conjugation types. |
Human KIR2DL4 knockout cell line |
|||
ABC-KH7929 | AcceGen | 1 vial | Ask for price |
Description: Human KIR2DL4 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
KIR2DL4 ORF Vector (Human) (pORF) |
|||
ORF005681 | ABM | 1.0 ug DNA | EUR 114 |
Human KIR2DL4 knockdown cell line |
|||
ABC-KD7929 | AcceGen | 1 vial | Ask for price |
Description: Human KIR2DL4 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
Human KIR2DL4 Protein Lysate 20ug |
|||
IHUKIR2DL4PLLY20UG | Innovative research | each | EUR 213 |
Description: Human KIR2DL4 Protein Lysate 20ug |
KIR2DL4 |
|||
CSB-CL857457HU | Cusabio | 10 μg plasmid + 200μl Glycerol | Ask for price |
KIR2DL4 |
|||
pro-2460 | ProSpec Tany | 1µg | EUR 60 |
Description: Recombinant Human Killer Cell Immunoglobulin-Like Receptor, 2 Domains Long Cytoplasmic Tail 4 |
KIR2DL4 |
|||
MBS8561736-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
KIR2DL4 |
|||
MBS8561736-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
KIR2DL4 |
|||
MBS8561736-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
KIR2DL4 |
|||
MBS8561736-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
KIR2DL4 |
|||
MBS8561736-02mL | MyBiosource | 0.2mL | EUR 345 |
KIR2DL4 |
|||
MBS8535639-01mL | MyBiosource | 0.1mL | EUR 325 |
KIR2DL4 |
|||
MBS8535639-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
KIR2DL4 |
|||
MBS8535639-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
KIR2DL4 |
|||
MBS8535639-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
KIR2DL4 |
|||
MBS8535639-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
KIR2DL4 (NM_002255) Human Over-expression Lysate |
|||
LS003805 | BosterBio | 100ug | EUR 628 |
Description: Transient overexpression lysate of killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4), transcript variant 1 |
Recombinant Human KIR2DL4/CD158D Protein |
|||
PKSH030752-100ug | Elabscience Biotech | 100ug | EUR 732 |
Description: Human |
Recombinant Human KIR2DL4 / CD158D Protein |
|||
MBS2545425-01mg | MyBiosource | 0.1mg | EUR 685 |
Recombinant Human KIR2DL4 / CD158D Protein |
|||
MBS2545425-5x01mg | MyBiosource | 5x0.1mg | EUR 3080 |
KIR2DL4 Antibody |
|||
DF13591 | Affbiotech | 100ul | EUR 420 |
KIR2DL4 Antibody |
|||
DF13591-100ul | Affinity Biosciences | 100ul | EUR 280 |
KIR2DL4 Antibody |
|||
DF13591-200ul | Affinity Biosciences | 200ul | EUR 350 |
KIR2DL4 Antibody |
|||
E912836 | EnoGene | 100ul | EUR 255 |
Description: Available in various conjugation types. |
KIR2DL4 Antibody |
|||
E309374 | EnoGene | 200ul | EUR 275 |
Description: Available in various conjugation types. |
KIR2DL4 antibody |
|||
70R-2365 | Fitzgerald | 50 ug | EUR 467 |
Description: Rabbit polyclonal KIR2DL4 antibody raised against the middle region of KIR2DL4 |
KIR2DL4 Antibody |
|||
GWB-MP022D | GenWay Biotech | 50ug | Ask for price |
KIR2DL4 Antibody |
|||
MBS9612350-01mL | MyBiosource | 0.1mL | EUR 260 |
KIR2DL4 Antibody |
|||
MBS9612350-02mL | MyBiosource | 0.2mL | EUR 305 |
KIR2DL4 Antibody |
|||
MBS9612350-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
Human KIR2DL4 / CD158d Protein, Fc Tag |
|||
KI4-H5255 | ACROBIOSYSTEMS | 100ug | EUR 2749.9 |
Description: Human KIR2DL4, Fc Tag (KI4-H5255) is expressed from human 293 cells (HEK293). It contains AA His 24 - His 242 (Accession # Q99706-1). |
Recombinant Human KIR2DL4 Protein, His Tag |
|||
E40KMH1307 | EnoGene | 20ug | EUR 495 |
Recombinant Human KIR2DL4 protein (C-6His) |
|||
CD01424-10ug | Jiaxing Korain Biotech Ltd (BT Labs) | 10ug | EUR 188 |
Description: Recombinant Human Killer Cell immunoglobulin-like Receptor 2DL4 is produced by our Mammalian expression system and the target gene encoding Trp22-His242 is expressed with a 6His tag at the C-terminus. |
Recombinant Human KIR2DL4 protein (C-6His) |
|||
CD01424-50ug | Jiaxing Korain Biotech Ltd (BT Labs) | 50ug | EUR 517 |
Description: Recombinant Human Killer Cell immunoglobulin-like Receptor 2DL4 is produced by our Mammalian expression system and the target gene encoding Trp22-His242 is expressed with a 6His tag at the C-terminus. |
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
AP75042 | SAB | 1mg | EUR 3209 |
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
C310-10ug | Novoprotein | 10ug | EUR 157.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
C310-1mg | Novoprotein | 1mg | EUR 2739.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
C310-500ug | Novoprotein | 500ug | EUR 1935.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
Recombinant Human KIR2DL4/CD158d/KIR103 (C-6His) |
|||
C310-50ug | Novoprotein | 50ug | EUR 327.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4. |
KIR2DL4 Protein, Human, Recombinant (hFc Tag) |
|||
MBS8121252-01mg | MyBiosource | 0.1mg | EUR 395 |
KIR2DL4 Protein, Human, Recombinant (hFc Tag) |
|||
MBS8121252-5x01mg | MyBiosource | 5x0.1mg | EUR 1635 |
KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
20-abx210854 | Abbexa |
|
|
KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
20-abx339417 | Abbexa |
|
|
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
1-CSB-PA205578 | Cusabio |
|
|
Description: A polyclonal antibody against KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4. Recognizes KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
1-CSB-PA246816 | Cusabio |
|
|
Description: A polyclonal antibody against KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4. Recognizes KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:50-1:100 |
KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
abx210854-100l | Abbexa | 100 µl | EUR 350 |
KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
abx210854-50l | Abbexa | 50 µl | EUR 250 |
KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
abx339417-100l | Abbexa | 100 µl | EUR 350 |
KIR2DL3 / KIR2DL1 / KIR2DL4 / KIR2DS4 Antibody |
|||
abx339417-50l | Abbexa | 50 µl | EUR 250 |
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
MBS7125228-005mL | MyBiosource | 0.05mL | EUR 190 |
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
MBS7125228-01mL | MyBiosource | 0.1mL | EUR 270 |
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
MBS7125228-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
MBS7125229-005mL | MyBiosource | 0.05mL | EUR 190 |
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
MBS7125229-01mL | MyBiosource | 0.1mL | EUR 270 |
KIR2DL3/KIR2DL1/KIR2DL4/KIR2DS4 Antibody |
|||
MBS7125229-5x01mL | MyBiosource | 5x0.1mL | EUR 1205 |
Human KIR2DL4 CHO Stable Overexpression Lysate |
|||
MBS8115009-03mg | MyBiosource | 0.3mg | EUR 280 |
Human KIR2DL4 CHO Stable Overexpression Lysate |
|||
MBS8115009-5x03mg | MyBiosource | 5x0.3mg | EUR 1205 |
Human KIR2DL4 CHO Stable Overexpression Lysate |
|||
MBS8115010-03mg | MyBiosource | 0.3mg | EUR 280 |
Human KIR2DL4 CHO Stable Overexpression Lysate |
|||
MBS8115010-5x03mg | MyBiosource | 5x0.3mg | EUR 1205 |
KIR2DL4 sgRNA CRISPR Lentivector set (Human) |
|||
K1150301 | ABM | 3 x 1.0 ug | EUR 406.8 |
KIR2DL4 siRNA |
|||
20-abx921662 | Abbexa |
|
|
Recombinant Human KIR2DL4 protein, C-His Tag |
|||
MBS1560850-005mg | MyBiosource | 0.05mg | EUR 345 |
Recombinant Human KIR2DL4 protein, C-His Tag |
|||
MBS1560850-01mg | MyBiosource | 0.1mg | EUR 450 |
Recombinant Human KIR2DL4 protein, C-His Tag |
|||
MBS1560850-5x01mg | MyBiosource | 5x0.1mg | EUR 1710 |
KIR2DL4 Protein Vector (Human) (pPM-C-HA) |
|||
PV022723 | ABM | 500 ng | EUR 394.8 |
KIR2DL4 Protein Vector (Human) (pPB-C-His) |
|||
PV022721 | ABM | 500 ng | EUR 394.8 |
KIR2DL4 Protein Vector (Human) (pPB-N-His) |
|||
PV022722 | ABM | 500 ng | EUR 394.8 |
KIR2DL4 Protein Vector (Human) (pPM-C-His) |
|||
PV022724 | ABM | 500 ng | EUR 394.8 |
KIR2DL4, 24-242aa, Human, hIgG-His-tag, Baculovirus |
|||
MBS206689-001mg | MyBiosource | 0.01mg | EUR 340 |
KIR2DL4, 24-242aa, Human, hIgG-His-tag, Baculovirus |
|||
MBS206689-005mg | MyBiosource | 0.05mg | EUR 985 |
KIR2DL4, 24-242aa, Human, hIgG-His-tag, Baculovirus |
|||
MBS206689-5x005mg | MyBiosource | 5x0.05mg | EUR 4180 |
Recombinant Human KIR2DL4/CD158D Protein (His Tag) |
|||
PKSH032675-10ug | Elabscience Biotech | 10ug | EUR 98 |
Description: Human |
Recombinant Human KIR2DL4/CD158D Protein (His Tag) |
|||
PKSH032675-50ug | Elabscience Biotech | 50ug | EUR 262 |
Description: Human |
KIR2DL4 Polyclonal Antibody |
|||
27806 | SAB | 100ul | EUR 439 |
KIR2DL4 Polyclonal Antibody |
|||
27806-100ul | SAB | 100ul | EUR 302.4 |
KIR2DL4 Polyclonal Antibody |
|||
27806-50ul | SAB | 50ul | EUR 224.4 |
KIR2DL4 Polyclonal Antibody |
|||
E-AB-64343-120uL | Elabscience Biotech | 120uL | EUR 320 |
Description: Unconjugated |
KIR2DL4 Polyclonal Antibody |
|||
E-AB-64343-200uL | Elabscience Biotech | 200uL | EUR 530 |
Description: Unconjugated |
KIR2DL4 Polyclonal Antibody |
|||
E-AB-64343-60uL | Elabscience Biotech | 60uL | EUR 200 |
Description: Unconjugated |
KIR2DL4 Polyclonal Antibody |
|||
E-AB-64343-each | Elabscience Biotech | each | Ask for price |
Description: Unconjugated |
KIR2DL4 Polyclonal Antibody |
|||
MBS9132645-002mL | MyBiosource | 0.02mL | EUR 200 |
KIR2DL4 Polyclonal Antibody |
|||
MBS9132645-005mL | MyBiosource | 0.05mL | EUR 255 |
KIR2DL4 Polyclonal Antibody |
|||
MBS9132645-01mL | MyBiosource | 0.1mL | EUR 345 |
KIR2DL4 Polyclonal Antibody |
|||
MBS9132645-02mL | MyBiosource | 0.2mL | EUR 545 |
KIR2DL4 Polyclonal Antibody |
|||
MBS9132645-5x02mL | MyBiosource | 5x0.2mL | EUR 2265 |
KIR2DL4 Polyclonal Antibody |
|||
MBS2554718-006mL | MyBiosource | 0.06mL | EUR 190 |
KIR2DL4 Polyclonal Antibody |
|||
MBS2554718-012mL | MyBiosource | 0.12mL | EUR 265 |
KIR2DL4 Polyclonal Antibody |
|||
MBS2554718-02mL | MyBiosource | 0.2mL | EUR 415 |
KIR2DL4 Polyclonal Antibody |
|||
MBS2554718-5x02mL | MyBiosource | 5x0.2mL | EUR 1835 |
KIR2DL4 Polyclonal Antibody |
|||
MBS9431682-005mL | MyBiosource | 0.05mL | EUR 300 |
KIR2DL4 Polyclonal Antibody |
|||
MBS9431682-01mL | MyBiosource | 0.1mL | EUR 390 |
KIR2DL4 Polyclonal Antibody |
|||
MBS9431682-5x01mL | MyBiosource | 5x0.1mL | EUR 1610 |
KIR2DL4 Polyclonal Antibody |
|||
RD81108A-120uL | Reddot Biotech | 120μL | EUR 360 |
Description: Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR genes are polymorphic and highly homologous and they are found in a cluster on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The gene content of the KIR gene cluster varies among haplotypes, although several 'framework' genes are found in all haplotypes (KIR3DL3, KIR3DP1, KIR3DL4, KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins with the short cytoplasmic domain lack the ITIM motif and instead associate with the TYRO protein tyrosine kinase binding protein to transduce activating signals. The ligands for several KIR proteins are subsets of HLA class I molecules; thus, KIR proteins are thought to play an important role in regulation of the immune response. This gene is one of the 'framework' loci that is present on all haplotypes. Alternate alleles of this gene are represented on multiple alternate reference loci (ALT_REF_LOCs). Alternative splicing results in multiple transcript variants, some of which may not be annotated on the primary reference assembly. |
KIR2DL4 Polyclonal Antibody |
|||
RD81108A-200uL | Reddot Biotech | 200μL | EUR 630 |
Description: Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR genes are polymorphic and highly homologous and they are found in a cluster on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The gene content of the KIR gene cluster varies among haplotypes, although several 'framework' genes are found in all haplotypes (KIR3DL3, KIR3DP1, KIR3DL4, KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins with the short cytoplasmic domain lack the ITIM motif and instead associate with the TYRO protein tyrosine kinase binding protein to transduce activating signals. The ligands for several KIR proteins are subsets of HLA class I molecules; thus, KIR proteins are thought to play an important role in regulation of the immune response. This gene is one of the 'framework' loci that is present on all haplotypes. Alternate alleles of this gene are represented on multiple alternate reference loci (ALT_REF_LOCs). Alternative splicing results in multiple transcript variants, some of which may not be annotated on the primary reference assembly. |
KIR2DL4 Polyclonal Antibody |
|||
RD81108A-60uL | Reddot Biotech | 60μL | EUR 204 |
Description: Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells and subsets of T cells. The KIR genes are polymorphic and highly homologous and they are found in a cluster on chromosome 19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The gene content of the KIR gene cluster varies among haplotypes, although several 'framework' genes are found in all haplotypes (KIR3DL3, KIR3DP1, KIR3DL4, KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and by whether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduce inhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins with the short cytoplasmic domain lack the ITIM motif and instead associate with the TYRO protein tyrosine kinase binding protein to transduce activating signals. The ligands for several KIR proteins are subsets of HLA class I molecules; thus, KIR proteins are thought to play an important role in regulation of the immune response. This gene is one of the 'framework' loci that is present on all haplotypes. Alternate alleles of this gene are represented on multiple alternate reference loci (ALT_REF_LOCs). Alternative splicing results in multiple transcript variants, some of which may not be annotated on the primary reference assembly. |
Recombinant Human KIR2DL4 Protein, His, Insect-1ug |
|||
QP12489-1ug | EnQuireBio | 1ug | EUR 186 |
Recombinant Human KIR2DL4 Protein, His, Insect-5ug |
|||
QP12489-5ug | EnQuireBio | 5ug | EUR 241.2 |
ABflo® 488 Rabbit anti-Human KIR2DL4/CD158d mAb |
|||
A24367 | Abclonal | 500T | EUR 201.92 |
ABflo® 647 Rabbit anti-Human KIR2DL4/CD158d mAb |
|||
A24368 | Abclonal | 200T | EUR 201.92 |
ABflo® 594 Rabbit anti-Human KIR2DL4/CD158d mAb |
|||
A24369 | Abclonal | 100T | EUR 531.38 |
Recombinant Human KIR2DL4 Protein, His, Insect-50ug |
|||
QP12489-50ug | EnQuireBio | 50ug | EUR 1513.2 |
Recombinant Human KIR2DL4/CD158d/KIR103 Protein (C-6His) |
|||
MBS2552885-001mg | MyBiosource | 0.01mg | EUR 160 |
Recombinant Human KIR2DL4/CD158d/KIR103 Protein (C-6His) |
|||
MBS2552885-005mg | MyBiosource | 0.05mg | EUR 285 |
Recombinant Human KIR2DL4/CD158d/KIR103 Protein (C-6His) |
|||
MBS2552885-5x005mg | MyBiosource | 5x0.05mg | EUR 1265 |
Recombinant Human CD158D/KIR2DL4 Protein, His Tag |
|||
E40KMH335 | EnoGene | 20ug | EUR 495 |
KIR2DL4 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
K1150302 | ABM | 1.0 ug DNA | EUR 184.8 |
KIR2DL4 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
K1150303 | ABM | 1.0 ug DNA | EUR 184.8 |
KIR2DL4 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
K1150304 | ABM | 1.0 ug DNA | EUR 184.8 |
KIR2DL4 Antibody (C-term) |
|||
MBS9206977-008mL | MyBiosource | 0.08mL | EUR 210 |
KIR2DL4 Antibody (C-term) |
|||
MBS9206977-04mL | MyBiosource | 0.4mL | EUR 430 |
KIR2DL4 Antibody (C-term) |
|||
MBS9206977-5x04mL | MyBiosource | 5x0.4mL | EUR 1910 |
KIR2DL4 Rabbit pAb |
|||
A12836-100ul | Abclonal | 100 ul | EUR 369.6 |
KIR2DL4 Rabbit pAb |
|||
A12836-200ul | Abclonal | 200 ul | EUR 550.8 |
KIR2DL4 Rabbit pAb |
|||
A12836-20ul | Abclonal | 20 ul | EUR 219.6 |
KIR2DL4 Rabbit pAb |
|||
A12836-50ul | Abclonal | 50 ul | EUR 267.6 |
KIR2DL4 Rabbit pAb |
|||
E2511314 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
KIR2DL4 Rabbit mAb |
|||
A23918 | Abclonal | 200μL | EUR 1557.4 |
Description: Recombinant fusion protein containing a sequence corresponding to amino acids 1-120 of human p70 S6 Kinase 2 (Q9UBS0). |
KIR2DL4 cDNA Clone |
|||
MBS1274433-001mgPlasmid02mLGlycerolStock | MyBiosource | 0.01mgPlasmid+0.2mLGlycerol-Stock | EUR 200 |
KIR2DL4 cDNA Clone |
|||
MBS1274433-5x001mgPlasmid5x02mLGlycerolStock | MyBiosource | 5x0.01mgPlasmid+5x0.2mLGlycerol-Stock | EUR 855 |
KIR2DL4 Rabbit pAb |
|||
MBS8548539-01mL | MyBiosource | 0.1mL | EUR 305 |
KIR2DL4 Rabbit pAb |
|||
MBS8548539-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
KIR2DL4 Rabbit pAb |
|||
MBS8548539-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
KIR2DL4 Rabbit pAb |
|||
MBS8548539-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
KIR2DL4 Rabbit pAb |
|||
MBS8548539-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
KIR2DL4 Rabbit pAb |
|||
A12836 | Abclonal | 100μL | EUR 1246.96 |
KIR2DL4 antibody - middle region |
|||
MBS3206160-01mL | MyBiosource | 0.1mL | EUR 455 |
KIR2DL4 antibody - middle region |
|||
MBS3206160-5x01mL | MyBiosource | 5x0.1mL | EUR 1995 |
KIR2DL4 cloning plasmid |
|||
CSB-CL857457HU-10ug | Cusabio | 10ug | EUR 279.6 |
Description: A cloning plasmid for the KIR2DL4 gene. |
KIR2DL4 Blocking Peptide |
|||
33R-9831 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of KIR2DL4 antibody, catalog no. 70R-2365 |
KIR2DL4 Blocking Peptide |
|||
MBS9622294-1mg | MyBiosource | 1mg | EUR 380 |
KIR2DL4 Blocking Peptide |
|||
MBS9622294-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
OAEE00659-100T - KIR2DL4 Antibody |
|||
OAEE00659-100T | Aviva Systems Biology | 100tests | EUR 299 |
OAEE00660-100T - KIR2DL4 Antibody |
|||
OAEE00660-100T | Aviva Systems Biology | 100tests | EUR 299 |
OAEE00101-100UG - KIR2DL4 Antibody |
|||
OAEE00101-100UG | Aviva Systems Biology | 0.1mg | EUR 259 |
OAGA02475-100UL - KIR2DL4 Antibody |
|||
OAGA02475-100UL | Aviva Systems Biology | 100ul | EUR 369 |
KIR2DL4 Rabbit Polyclonal Antibody |
|||
E10G30445 | EnoGene | 100 μl | EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
KIR2DL4 Recombinant Protein |
|||
91-290 | ProSci | 0.05 mg | EUR 556.8 |
Description: Killer cell immunoglobulin-like receptor 2DL4(KIR2DL4) is a Single-pass type I membrane protein and contains 2 Ig-like C2-type (immunoglobulin-like) domains.It belongs to the immunoglobulin superfamily. KIR2DL4 is expressed in all NK cells and some T cells. KIR2DL4 activates the cytotoxicity of NK cells, despite the presence of an immunoreceptor tyrosine-based inhibition motif (ITIM) in its cytoplasmic tail. The ITIM was not necessary for activation of lysis by KIR2DL4. The activation signal of KIR2DL4 was sensitive to inhibition by another ITIM-containing receptor. The activation-deficient mutant of KIR2DL4 inhibited the signal delivered by the activating receptor CD16. |
KIR2DL4 Polyclonal Conjugated Antibody |
|||
C27806 | SAB | 100ul | EUR 476.4 |
KIR2DL4 Polyclonal Conjugated Antibody |
|||
MBS9439697-01mLAF350 | MyBiosource | 0.1mL(AF350) | EUR 480 |
KIR2DL4 Polyclonal Conjugated Antibody |
|||
MBS9439697-01mLAF405 | MyBiosource | 0.1mL(AF405) | EUR 480 |
KIR2DL4 Polyclonal Conjugated Antibody |
|||
MBS9439697-01mLAF488 | MyBiosource | 0.1mL(AF488) | EUR 480 |
KIR2DL4 Polyclonal Conjugated Antibody |
|||
MBS9439697-01mLAF555 | MyBiosource | 0.1mL(AF555) | EUR 480 |
KIR2DL4 Polyclonal Conjugated Antibody |
|||
MBS9439697-01mLBiotin | MyBiosource | 0.1mL(Biotin) | EUR 480 |
Human KIR2DL4 Recombinant Protein C-6 His Tag Lyophilized |
|||
IHUKIR2DL4RC6HISLY50UG | Innovative research | each | EUR 640 |
Description: Human KIR2DL4 Recombinant Protein C-6 His Tag Lyophilized |
Human KIR2DL4 Recombinant Protein C-6 His Tag Lyophilized |
|||
MBS8432586-INQUIRE | MyBiosource | INQUIRE | Ask for price |
KIR2DL4 (untagged)-Human killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4), transcript variant 3 |
|||
SC315741 | Origene Technologies GmbH | 10 µg | Ask for price |
KIR2DL4 (untagged)-Human killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4), transcript variant 1 |
|||
SC126103 | Origene Technologies GmbH | 10 µg | Ask for price |
KIR2DL4 (untagged)-Human killer cell immunoglobulin-like receptor, two domains, long cytoplasmic tail, 4 (KIR2DL4), transcript variant 2 |
|||
SC319875 | Origene Technologies GmbH | 10 µg | Ask for price |
KIR2DL4 Antibody - C-terminal region |
|||
MBS3220312-01mL | MyBiosource | 0.1mL | EUR 455 |
KIR2DL4 Antibody - C-terminal region |
|||
MBS3220312-5x01mL | MyBiosource | 5x0.1mL | EUR 1995 |
KIR2DL4 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each |
|||
SR320789 | Origene Technologies GmbH | 2 nmol | Ask for price |
Replication-competent vesicular stomatitis virus vaccine vector protects in opposition to SARS-CoV-2-mediated pathogenesis
Extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has prompted hundreds of thousands of human infections and tons of of 1000’s of deaths. Accordingly, an efficient vaccine is of crucial significance in mitigating coronavirus induced illness 2019 (COVID-19) and curbing the pandemic. We developed a replication-competent vesicular stomatitis virus (VSV)-based vaccine by introducing a modified type of the SARS-CoV-2 spike gene instead of the native glycoprotein gene (VSV-eGFP-SARS-CoV-2). Immunization of mice with VSV-eGFP-SARS-CoV-2 elicits excessive titers of antibodies that neutralize SARS-CoV-2 an infection and goal the receptor binding area that engages human angiotensin changing enzyme-2 (ACE2).
Upon problem with a human isolate of SARS-CoV-2, mice expressing human ACE2 and immunized with VSV-eGFP-SARS-CoV-2 present profoundly decreased viral an infection and irritation within the lung indicating safety in opposition to pneumonia. Lastly, passive switch of sera from VSV-eGFP-SARS-CoV-2-immunized animals protects naïve mice from SARS-CoV-2 problem. These information help growth of VSV-eGFP-SARS-CoV-2 as an attenuated, replication-competent vaccine in opposition to SARS-CoV-2.
The non-viral vectors and essential strategies of loading siRNA onto the titanium implants and their software
Floor modification of titanium implants by siRNA is kind of environment friendly for bettering implant osseointegration. Loading siRNA onto their floor is a vital issue for siRNA-functionalized implants to appreciate their organic operate. Direct binding of siRNA to implants has low siRNA binding and releasing price, so often it must be mediated by vectors.
Polymeric, nonmaterial-mediated and lipid-based vectors are kinds of non-viral vectors that are generally used for delivering siRNA. Three main strategies of loading course of, particularly easy bodily adsorption, layer-by-layer meeting and electrodeposition, are additionally summarized. A quick introduction, the essential precept and the overall process of every methodology are included.
The loading effectivity, which might be measured each qualitatively and quantitatively, along with gene knockdown effectivity, cytotoxicity assay and osteogenesis of the three strategies are in contrast. An excellent many functions in osteogenesis have additionally been described on this evaluate.
Manufacturing of high-titer transmission-defective RNA virus-based episomal vector utilizing tangential stream filtration
Lately, viral vector based mostly in vivo gene supply methods have achieved a important success within the remedy of genetic ailments. RNA virus-based episomal vector missing viral glycoprotein gene (ΔG-REVec) is a non-transmissive gene supply system that permits long-term gene expression in number of cell sorts in vitro, but in vivo gene supply has not been profitable because of issue in manufacturing of excessive titer vector.
Within the current examine, we present that tangential stream filtration (TFF) might be successfully employed to extend titer of ΔG-REVec. Focus and diafiltration of ΔG-REVec utilizing TFF considerably elevated its titer with out lack of infectious exercise. Importantly, intracranial administration of excessive titer vector enabled persistent transgene expression in rodent mind. This text is protected by copyright. All rights reserved.
|
|||
MBS212047-02mg | MyBiosource | 0.2mg | EUR 500 |
|
|||
MBS212047-5x02mg | MyBiosource | 5x0.2mg | EUR 2070 |
|
|||
MBS212048-01mg | MyBiosource | 0.1mg | EUR 355 |
|
|||
MBS212048-5x01mg | MyBiosource | 5x0.1mg | EUR 1425 |
|
|||
MBS214373-02mg | MyBiosource | 0.2mg | EUR 500 |
|
|||
MBS214373-5x02mg | MyBiosource | 5x0.2mg | EUR 2070 |
|
|||
MBS214830-0025mg | MyBiosource | 0.025mg | EUR 210 |
|
|||
MBS214830-5x0025mg | MyBiosource | 5x0.025mg | EUR 765 |
|
|||
MBS216231-0025mg | MyBiosource | 0.025mg | EUR 210 |
|
|||
MBS216231-5x0025mg | MyBiosource | 5x0.025mg | EUR 765 |
|
|||
MBS224555-01mg | MyBiosource | 0.1mg | EUR 355 |
|
|||
MBS224555-5x01mg | MyBiosource | 5x0.1mg | EUR 1425 |
|
|||
MBS224741-02mg | MyBiosource | 0.2mg | EUR 500 |
|
|||
MBS224741-5x02mg | MyBiosource | 5x0.2mg | EUR 2070 |
|
|||
MBS214375-100Tests | MyBiosource | 100Tests | EUR 520 |
|
|||
MBS214375-5x100Tests | MyBiosource | 5x100Tests | EUR 2160 |
|
|||
MBS226106-100Tests | MyBiosource | 100Tests | EUR 520 |
|
|||
MBS226106-5x100Tests | MyBiosource | 5x100Tests | EUR 2160 |
|
|||
MBS210627-01mg | MyBiosource | 0.1mg | EUR 435 |
|
|||
MBS210627-5x01mg | MyBiosource | 5x0.1mg | EUR 1785 |
|
|||
MBS214829-0025mg | MyBiosource | 0.025mg | EUR 210 |
|
|||
MBS214829-5x0025mg | MyBiosource | 5x0.025mg | EUR 765 |
|
|||
MBS224692-01mg | MyBiosource | 0.1mg | EUR 435 |
|
|||
MBS224692-5x01mg | MyBiosource | 5x0.1mg | EUR 1785 |
|
|||
MBS210312-01mg | MyBiosource | 0.1mg | EUR 435 |
|
|||
MBS210312-5x01mg | MyBiosource | 5x0.1mg | EUR 1785 |
|
|||
MBS214374-01mg | MyBiosource | 0.1mg | EUR 435 |
|
|||
MBS214374-5x01mg | MyBiosource | 5x0.1mg | EUR 1785 |
|
|||
MBS216230-0025mg | MyBiosource | 0.025mg | EUR 210 |
|
|||
MBS216230-5x0025mg | MyBiosource | 5x0.025mg | EUR 765 |
|
|||
MBS550098-05mg | MyBiosource | 0.5mg | EUR 515 |
|
|||
MBS550098-1mg | MyBiosource | 1mg | EUR 830 |
|
|||
MBS239316-01mg | MyBiosource | 0.1mg | EUR 485 |
|
|||
MBS239316-5x01mg | MyBiosource | 5x0.1mg | EUR 2005 |
|
|||
MBS211192-05mg | MyBiosource | 0.5mg | EUR 775 |
|
|||
MBS211192-5x05mg | MyBiosource | 5x0.5mg | EUR 3310 |
|
|||
CABT-45643RH | Creative Diagnostics | 0.2 mg | EUR 889.2 |
|
|||
MBS225847-01mg | MyBiosource | 0.1mg | EUR 520 |
|
|||
MBS225847-5x01mg | MyBiosource | 5x0.1mg | EUR 2160 |
|
|||
CABT-45628MH | Creative Diagnostics | 0.1 mg | EUR 639.6 |
|
|||
CABT-45641MH | Creative Diagnostics | 0.2 mg | EUR 920.4 |
|
|||
32894-05111 | AssayPro | 150 ug | EUR 215 |
|
|||
CABT-45642MH | Creative Diagnostics | 100 TEST | EUR 852 |
|
|||
mab-SF-C048 | Antagene | 0.2mg | EUR 180 |
|
|||
CABT-45622MH | Creative Diagnostics | 0.1 mg | EUR 852 |
|
|||
GWB-83A580 | GenWay Biotech | 0.2 mg | Ask for price |
|
|||
E16FHP016-025 | EnoGene | 25 tests | EUR 293.67 |
Description: Available in various conjugation types. |
|
|||
E16FHP016-050 | EnoGene | 50 tests | EUR 419.33 |
Description: Available in various conjugation types. |
|
|||
E16FHP016-100 | EnoGene | 100 Tests | EUR 629 |
Description: Available in various conjugation types. |
|
|||
MBS696807-100Tests | MyBiosource | 100Tests | EUR 350 |
|
|||
MBS696807-25Tests | MyBiosource | 25Tests | EUR 215 |
|
|||
MBS696807-5x100Tests | MyBiosource | 5x100Tests | EUR 1530 |
|
|||
101-M290 | ReliaTech | 100 µg | EUR 399 |
Description: Receptors that recognize the Fc portion of IgG are divided into three groups designated Fc gamma RI, RII, and RIII, also known respectively as CD64, CD32, and CD16. In humans each group of receptors is encoded by 2 - 3 closely related genes designated A, B, and C. Fc gamma RI binds IgG with high affinity and functions during early immune responses. Fc gamma RII and RIII are low affinity receptors that recognize IgG as aggregates surrounding multivalent antigens during late immune responses. Different Fc receptors can function as activators, as inhibitors, or as decoy receptors. |
|
|||
E16FHA016-025 | EnoGene | 25 tests | EUR 293.67 |
Description: Available in various conjugation types. |
|
|||
E16FHA016-050 | EnoGene | 50 tests | EUR 419.33 |
Description: Available in various conjugation types. |
|
|||
E16FHA016-100 | EnoGene | 100 Tests | EUR 629 |
Description: Available in various conjugation types. |
|
|||
MBS696798-100Tests | MyBiosource | 100Tests | EUR 430 |
|
|||
MBS696798-25Tests | MyBiosource | 25Tests | EUR 225 |
|
|||
MBS696798-5x100Tests | MyBiosource | 5x100Tests | EUR 1900 |
|
|||
MBS9459444-25Tests | MyBiosource | 25Tests | EUR 230 |
|
|||
MBS9459444-50Tests | MyBiosource | 50Tests | EUR 290 |
|
|||
MBS9459444-5x50Tests | MyBiosource | 5x50Tests | EUR 1160 |
|
|||
E16FHF016-025 | EnoGene | 25 tests | EUR 222.33 |
Description: Available in various conjugation types. |
|
|||
E16FHF016-050 | EnoGene | 50 tests | EUR 317.67 |
Description: Available in various conjugation types. |
|
|||
E16FHF016-100 | EnoGene | 100 Tests | EUR 496 |
Description: Available in various conjugation types. |
|
|||
MBS696796-100Tests | MyBiosource | 100Tests | EUR 345 |
|
|||
MBS696796-25Tests | MyBiosource | 25Tests | EUR 195 |
|
|||
MBS696796-5x100Tests | MyBiosource | 5x100Tests | EUR 1510 |
|
|||
MBS696806-100Tests | MyBiosource | 100Tests | EUR 395 |
|
|||
MBS696806-25Tests | MyBiosource | 25Tests | EUR 235 |
|
|||
MBS696806-5x100Tests | MyBiosource | 5x100Tests | EUR 1740 |
|
|||
MBS9459512-25Tests | MyBiosource | 25Tests | EUR 230 |
|
|||
MBS9459512-50Tests | MyBiosource | 50Tests | EUR 290 |
|
|||
MBS9459512-5x50Tests | MyBiosource | 5x50Tests | EUR 1160 |
|
|||
E16FHR016-025 | EnoGene | 25 tests | EUR 563.33 |
Description: Available in various conjugation types. |
|
|||
E16FHR016-100 | EnoGene | 100 tests | EUR 1235 |
Description: Available in various conjugation types. |
|
|||
E16FHR016CX-025 | EnoGene | 25 tests | EUR 390 |
Description: Available in various conjugation types. |
|
|||
E16FHR016CX-100 | EnoGene | 100 tests | EUR 1061.67 |
Description: Available in various conjugation types. |
|
|||
MBS666071-01mg | MyBiosource | 0.1mg | EUR 1145 |
|
|||
MBS666071-5x01mg | MyBiosource | 5x0.1mg | EUR 5005 |
|
|||
E16FHB016-025 | EnoGene | 25 tests | EUR 231.67 |
Description: Available in various conjugation types. |
|
|||
E16FHB016-050 | EnoGene | 50 tests | EUR 330.67 |
Description: Available in various conjugation types. |
|
|||
E16FHB016-100 | EnoGene | 100 Tests | EUR 496 |
Description: Available in various conjugation types. |
|
|||
E16FHB016-100U | EnoGene | 100 μg | EUR 330.67 |
Description: Available in various conjugation types. |
|
|||
E16FHB016-500U | EnoGene | 500 μg | EUR 1086 |
Description: Available in various conjugation types. |
|
|||
MBS666134-120Tests | MyBiosource | 120Tests | EUR 415 |
|
|||
MBS666134-5x120Tests | MyBiosource | 5x120Tests | EUR 1710 |
|
|||
MBS9459493-25Tests | MyBiosource | 25Tests | EUR 230 |
|
|||
MBS9459493-50Tests | MyBiosource | 50Tests | EUR 290 |
|
|||
MBS9459493-5x50Tests | MyBiosource | 5x50Tests | EUR 1160 |
|
|||
E16FHU016-100U | EnoGene | 100 μg | EUR 190.67 |
Description: Available in various conjugation types. |
|
|||
E16FHU016-500U | EnoGene | 500 μg | EUR 572 |
Description: Available in various conjugation types. |
|
|||
MBS666159-01mg | MyBiosource | 0.1mg | EUR 415 |
|
|||
MBS666159-5x01mg | MyBiosource | 5x0.1mg | EUR 1710 |
|
|||
16A2-100T | ImmunoStep | 100 test | EUR 339.9 |
|
|||
16F-100T | ImmunoStep | 100 test | EUR 215.6 |
|
|||
16F2-100T | ImmunoStep | 100 test | EUR 240.9 |
|
|||
16PE2-100T | ImmunoStep | 100 test | EUR 273.9 |
|
|||
16PU2-01MG | ImmunoStep | 0,1 mg | EUR 163.9 |
|
|||
E2790143 | EnoGene | 100ul | EUR 225 |
Description: Available in various conjugation types. |
|
|||
MBS8559190-01mL | MyBiosource | 0.1mL | EUR 305 |
|
|||
MBS8559190-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
|
|||
MBS8559190-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
|
|||
MBS8559190-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
|
|||
MBS8559190-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
|
|||
GWB-74F2BC | GenWay Biotech | 0.1 mg | Ask for price |
|
|||
DL20203F-20Tests | DL Develop | 20Tests | EUR 192.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
DL20203F-50Tests | DL Develop | 50Tests | EUR 267.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
RD20203F-100Tests | Reddot Biotech | 100Tests | EUR 255 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
RD20203F-100Testsx2 | Reddot Biotech | 100Testsx2 | EUR 360 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
RD20203F-20T | Reddot Biotech | 20(T) | EUR 97.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
RD30449F-100Tests | Reddot Biotech | 100Tests | EUR 285 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30449F-100Testsx2 | Reddot Biotech | 100Testsx2 | EUR 427.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30449F-20Tests | Reddot Biotech | 20Tests | EUR 112.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
MBS4165432-100Tests | MyBiosource | 100Tests | EUR 440 |
|
|||
MBS4165432-5x100Tests | MyBiosource | 5x100Tests | EUR 1720 |
|
|||
DL20204F-20Tests | DL Develop | 20Tests | EUR 192.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
DL20204F-50Tests | DL Develop | 50Tests | EUR 267.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
RD30450F-100Tests | Reddot Biotech | 100Tests | EUR 330 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30450F-100Testsx2 | Reddot Biotech | 100Testsx2 | EUR 495 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30450F-20Tests | Reddot Biotech | 20Tests | EUR 135 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
DL20202F-20Tests | DL Develop | 20Tests | EUR 192.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
DL20202F-50Tests | DL Develop | 50Tests | EUR 267.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
RD30448F-100Tests | Reddot Biotech | 100Tests | EUR 285 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30448F-100Testsx2 | Reddot Biotech | 100Testsx2 | EUR 427.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30448F-20Tests | Reddot Biotech | 20Tests | EUR 112.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
E16FHC016-025 | EnoGene | 25 tests | EUR 476.67 |
Description: Available in various conjugation types. |
|
|||
E16FHC016-100 | EnoGene | 100 tests | EUR 1083.33 |
Description: Available in various conjugation types. |
|
|||
E16FHN016-025 | EnoGene | 25 tests | EUR 563.33 |
Description: Available in various conjugation types. |
|
|||
E16FHN016-100 | EnoGene | 100 tests | EUR 1148.33 |
Description: Available in various conjugation types. |
|
|||
MBS666536-120Tests | MyBiosource | 120Tests | EUR 505 |
|
|||
MBS666536-5x120Tests | MyBiosource | 5x120Tests | EUR 2130 |
|
|||
DL20211F-20Tests | DL Develop | 20Tests | EUR 237.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
DL20211F-50Tests | DL Develop | 50Tests | EUR 335 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
RD30451F-100Tests | Reddot Biotech | 100Tests | EUR 337.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30451F-100Testsx2 | Reddot Biotech | 100Testsx2 | EUR 540 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30451F-20Tests | Reddot Biotech | 20Tests | EUR 135 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30455F-100Tests | Reddot Biotech | 100Tests | EUR 283.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30455F-100Testsx2 | Reddot Biotech | 100Testsx2 | EUR 487.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30455F-20Tests | Reddot Biotech | 20Tests | EUR 135 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30456F-100Tests | Reddot Biotech | 100Tests | EUR 283.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30456F-100Testsx2 | Reddot Biotech | 100Testsx2 | EUR 487.5 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
RD30456F-20Tests | Reddot Biotech | 20Tests | EUR 135 |
Description: CD16 is a 60 kD highly glycosylated protein. It is a member of the Ig superfamily and is also known as B7-1, B7, and Ly-53. CD16 is constitutively expressed on dendritic cells and monocytes/macrophages, and inducibly expressed on activated B and T cells. The ligation of CD28 on T cells with CD16 and CD86 (B7-2) on antigen presenting cells (such as dendritic cells, macrophages, and B cells) elicits co-stimulation of T cells resulting in enhanced cell activation, proliferation, and cytokine production. CD16 appears to be expressed later in the immune response than CD86. CD16 can also bind to CD152, also known as CTLA-4, to deliver an inhibitory signal to T cells. |
|
|||
FNab10139 | FN Test | 100µg | EUR 702 |
Description: Antibody raised against CD16 |
|
|||
E16FHO016-025 | EnoGene | 25 tests | EUR 563.33 |
Description: Available in various conjugation types. |
|
|||
E16FHO016-100 | EnoGene | 100 tests | EUR 1148.33 |
Description: Available in various conjugation types. |
|
|||
MBS674230-100Tests | MyBiosource | 100Tests | EUR 335 |
|
|||
MBS674230-5x100Tests | MyBiosource | 5x100Tests | EUR 1350 |
|
|||
DL20200F-100ug | DL Develop | 100μg | EUR 402.5 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
DL20200F-25ug | DL Develop | 25μg | EUR 185 |
Description: CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC). |
|
|||
E16FHS016-025 | EnoGene | 25 tests | EUR 650 |
Description: Available in various conjugation types. |
|
|||
E16FHS016-100 | EnoGene | 100 tests | EUR 1408.33 |
Description: Available in various conjugation types. |
|
|||
E16FHY016-050U | EnoGene | 50 μg | EUR 520 |
Description: Available in various conjugation types. |
|
|||
E16FHY016-1000U | EnoGene | 1 mg | EUR 2773.33 |
Description: Available in various conjugation types. |
|
|||
E16FHY016-500U | EnoGene | 500 μg | EUR 1516.67 |
Description: Available in various conjugation types. |
|
|||
E16FHZ016-1000U | EnoGene | 1 mg | EUR 2275 |
Description: Available in various conjugation types. |
|
|||
MBS674227-01mg | MyBiosource | 0.1mg | EUR 210 |
|
|||
MBS674227-5x01mg | MyBiosource | 5x0.1mg | EUR 785 |